Your browser doesn't support javascript.
loading
Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
Solomon, Michal; Ollech, Ayelet; Pavlotsky, Felix; Barzilai, Aviv; Schwartz, Eli; Baum, Sharon; Astman, Nadav.
Afiliación
  • Solomon M; Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel. solomondr1@gmail.com.
  • Ollech A; Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Pavlotsky F; Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Barzilai A; Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Schwartz E; The School of Medicine, Tel Aviv University, Tel Aviv, Israel; Center for Geographic Medicine and Tropical Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Baum S; Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Astman N; Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Acta Derm Venereol ; 104: adv35089, 2024 Apr 29.
Article en En | MEDLINE | ID: mdl-38682801
ABSTRACT
Israel is endemic for Old-World cutaneous leishmaniasis. The most common species is Leishmania major. However, the available treatment options are limited. This study's objective was to compare the authors' experience with different antimony intralesional treatments of Leishmania major cutaneous leishmaniasis. A retrospective evaluation was undertaken for cases of Leishmania major cutaneous leishmaniasis treated by pentavalent antimony in a university-affiliated medical centre in Israel. The previous treatment of intralesional sodium stibogluconate (Pentostam®) was compared with the current treatment of meglumine antimoniate (Glucantime®). One hundred cases of cutaneous leishmaniasis were treated during the study period, of whom 33 were treated with intralesional sodium stibogluconate and 67 were treated with intralesional meglumine antimoniate. The patients were 78 males and 22 females, mean age 24 (range 10-67) and there was a total of 354 skin lesions. Within 3 months from treatment, 91% (30/33) of the intralesional sodium stibogluconate group and 88% (59/67) of the intralesional meglumine antimoniate group had complete healing of the cutaneous lesions after an average of 3 treatment cycles (non-statistically significant). In conclusion, the 2 different medications have the same efficacy and safety for treating cutaneous leishmaniasis. Pentavalent antimoniate intralesional infiltration treatment is safe, effective, and well tolerated with minimal side effects for Old-World cutaneous leishmaniasis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inyecciones Intralesiones / Leishmaniasis Cutánea / Leishmania major / Gluconato de Sodio Antimonio / Antimoniato de Meglumina / Antiprotozoarios Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Acta Derm Venereol Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Suecia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inyecciones Intralesiones / Leishmaniasis Cutánea / Leishmania major / Gluconato de Sodio Antimonio / Antimoniato de Meglumina / Antiprotozoarios Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Acta Derm Venereol Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Suecia